Research Grade efitazanamivir alfa (HV080016)

Name: Research Grade efitazanamivir alfa
Brand: abinScience
SKU: HV080016
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HV080016
Description	efitazanamivir alfa (HV080016) is a research-grade recombinant antibody targeting Fc fragment of human immunoglobulin G1. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
Species reactivity	Human
Applications	ELISA, Functional assay, Research in vivo
Isotype	Fc fragment of human immunoglobulin G1
Species	Human
Clonality	Monoclonal
Target	Fc fragment of human immunoglobulin G1
Endotoxin level	< 10 EU/mg
Purity	>95% as determined by SDS-PAGE.
Accession	P01857
Form	Liquid
Reconstitution	Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	2781830-14-4
Background	Immunoglobulin heavy constant gamma 1 (Fc fragment of human immunoglobulin G1) is a ~43 kDa protein. Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. 1. Teng, G. et al. (2007) Annual review of genetics 41, 107-20. PMID: 17576170 2. Schroeder, HW. et al. (2010) The Journal of allergy and clinical immunology 125, S41-52. PMID: 20176268 3. McHeyzer-Williams, M. et al. (2011) Nature reviews. Immunology 12, 24-34. PMID: 22158414
Note	For research use only. Not suitable for clinical or therapeutic use.